- Conditions
- Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
- Interventions
- Erlotinib, Erlotinib Hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Ann Arbor, Michigan • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced May 22, 2026, 3:50 AM EDT